Numerous studies have linked coronavirus disease 2019 (COVID‐19) with endothelial dysfunction and reported elevated levels of endothelial biomarkers in this disease. We conducted a systematic review and meta‐analysis of the published evidence in this respect. A systematic literature search of PubMed and Scopus databases was performed to find studies investigating biomarkers of endothelial dysfunction in COVID‐19 patients. Pooled standardized mean differences and their 95% confidence intervals were calculated for each biomarker using random effect model. 74 studies with 7668 patients were included. In comparison to patients with good outcome, those with poor outcome had higher levels of von Willebrand factor (vWF) (SMD: 0.83, 95% CI: 0.59–1.07, p < 0.00001), vWF:ADAMTS13 (1.23, (0.77–1.7), p < 0.00001), angiopoietin‐2 (Ang‐2) (1.06 (0.6–1.51), p < 0.0001), E‐selectin (1.09 (0.55–1.63), p < 0.0001), P‐selectin (0.59 (0.24–0.94), p = 0.001), syndecan‐1 (0.99 (0.6–1.37), p < 0.00001), mid‐regional pro‐adrenomedullin (MR‐proADM) (1.52 (1.35–1.68), p < 0.00001), vascular endothelial growth factor (0.27 (0.02–0.53), p = 0.03), soluble fms‐like tyrosine kinase‐1 (sFLT‐1) (1.93 (0.65–3.21), p = 0.03) and lower levels of ADAMTS13 antigen (−0.69 (−0.9 to −0.47) p < 0.00001) and activity (−0.84 (−1.06 to −0.61) p < 0.0000). Plasminogen activator inhibitor‐1 and tissue plasminogen activator levels were not different between the two groups (p < 0.05). There were elevated levels of endothelial dysfunction biomarkers in COVID‐19 patients with poor outcome, indicating their possible role in disease severity and prognosis. In particular, MR‐proADM, vWF, syndecan‐1 and sFLT‐1 showed a significant association with poor outcome in these patients.